Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Serum deposition Cmax · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Adverse events · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) FEV1 · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Time to next exacerbation · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Participant satisfaction or preference · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR FEV1: change in FEV1 % predicted · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Intervention NR Treatment time (minutes) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 3 studies · 932 participants | Very low |
Intervention NR Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serum deposition Cmax · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 2 studies · 922 participants | Very low |
Intervention NR FEV1 · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 2 studies · 1146 participants | Low |
Intervention NR Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Treatment time · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Quality of life · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Serum deposition Cmax · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Adverse events · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD FEV1 · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Time to next exacerbation · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Participant satisfaction or preference · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Treatment time (minutes) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 85 participants | Low |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Quality of life CFQ‐R scores (treatment burden domain and respiratory domain) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 85 participants | Very low |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Serum deposition Cmax · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Adverse events · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 85 participants | Very low |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT FEV1 FEV1 % predicted · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 85 participants | Low |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | RR 2.33 [0.83, 6.54] | 101 participants | Very low |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Participant satisfaction or preference: · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | RR 0.48 [0.31, 0.76] | 1 study · 68 participants | Low |
Intervention NR Treatment time · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serum deposition Cmax · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR FEV1 · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 12 participants | Very low |
Intervention NR Time to next exacerbation · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Participant satisfaction or preference · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Treatment time · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Quality of life · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Treatment time: mean treatment time (min) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 4 studies · 103 participants | Low |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Serum deposition Cmax · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Adverse events · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 6 participants | Very low |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD FEV1 change from baseline · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 6 participants | Very low |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Time to next exacerbation · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Participant satisfaction or preference · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Treatment time (minutes) · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 13 participants | Very low |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Serum deposition Cmax · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Adverse events · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 15 participants | Very low |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) FEV1 · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | 1 study · 15 participants | Very low |